These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 18633238)

  • 21. Early pediatric anthracycline cardiotoxicity: managed by serial heart and bone marrow transplantation.
    Mangat JS; Rao K; Kingston J; Veys P; Amrolia P; Burch M
    J Heart Lung Transplant; 2007 Jun; 26(6):658-60. PubMed ID: 17543795
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Favourable outcome of patients with childhood acute promyelocytic leukaemia after treatment with reduced cumulative anthracycline doses.
    Creutzig U; Zimmermann M; Dworzak M; Urban C; Henze G; Kremens B; Lakomek M; Bourquin JP; Stary J; Reinhardt D
    Br J Haematol; 2010 May; 149(3):399-409. PubMed ID: 20230404
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pediatric AML patients with acute-onset cardiomyopathy in the setting of Streptococcus viridans bacteremia after anthracyclines.
    Sabet K; Panigrahi A; Chung J; Dayan Y
    Pediatr Blood Cancer; 2022 Feb; 69(2):e29450. PubMed ID: 34854543
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Chemotherapy-induced cardiotoxicity: Incidence, diagnosis and prevention].
    Nelson-Veniard M; Thambo JB
    Bull Cancer; 2015; 102(7-8):622-6. PubMed ID: 25935231
    [TBL] [Abstract][Full Text] [Related]  

  • 25. c-Jun N-terminal kinase activation failure is a new mechanism of anthracycline resistance in acute myeloid leukemia.
    Lagadinou ED; Ziros PG; Tsopra OA; Dimas K; Kokkinou D; Thanopoulou E; Karakantza M; Pantazis P; Spyridonidis A; Zoumbos NC
    Leukemia; 2008 Oct; 22(10):1899-908. PubMed ID: 18650843
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pediatric secondary chronic myeloid leukemia following cardiac transplantation for anthracycline-induced cardiomyopathy.
    Menon NM; Katsanis E; Khalpey Z; Whitlow P
    Pediatr Blood Cancer; 2015 Jan; 62(1):166-8. PubMed ID: 25175922
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anthracycline therapy can induce very early increase in QT dispersion and QTc prolongation.
    Pudil R; Horacek JM; Horackova J; Jebavy L; Vojacek J
    Leuk Res; 2008 Jun; 32(6):998-9. PubMed ID: 18001834
    [No Abstract]   [Full Text] [Related]  

  • 28. Epidemiology of anthracycline cardiotoxicity in children and adults.
    Grenier MA; Lipshultz SE
    Semin Oncol; 1998 Aug; 25(4 Suppl 10):72-85. PubMed ID: 9768828
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impaired exercise capacity and left ventricular function in long-term adult survivors of childhood acute lymphoblastic leukemia.
    Christiansen JR; Kanellopoulos A; Lund MB; Massey R; Dalen H; Kiserud CE; Ruud E; Aakhus S
    Pediatr Blood Cancer; 2015 Aug; 62(8):1437-43. PubMed ID: 25832752
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Myocardial dysfunction late after low-dose anthracycline treatment in asymptomatic pediatric patients.
    Ganame J; Claus P; Uyttebroeck A; Renard M; D'hooge J; Bijnens B; Sutherland GR; Eyskens B; Mertens L
    J Am Soc Echocardiogr; 2007 Dec; 20(12):1351-8. PubMed ID: 17604960
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiac complications in childhood cancer survivors treated with anthracyclines.
    Franco VI; Lipshultz SE
    Cardiol Young; 2015 Aug; 25 Suppl 2():107-16. PubMed ID: 26377717
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment of anthracycline-induced cardiotoxicity with biochemical markers.
    Horacek JM; Pudil R; Jebavy L; Tichy M; Zak P; Maly J
    Exp Oncol; 2007 Dec; 29(4):309-13. PubMed ID: 18199989
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Late cardiac effects of anthracycline containing therapy for childhood acute lymphoblastic leukemia.
    Rathe M; Carlsen NL; Oxhøj H
    Pediatr Blood Cancer; 2007 Jun; 48(7):663-7. PubMed ID: 17405151
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anthracycline cardiotoxicity after breast cancer treatment.
    Hershman DL; Shao T
    Oncology (Williston Park); 2009 Mar; 23(3):227-34. PubMed ID: 19418823
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessing the risk of heart failure in patients with acute leukemia.
    Scherrer-Crosbie M
    Clin Adv Hematol Oncol; 2020 Apr; 18(4):202-203. PubMed ID: 32628647
    [No Abstract]   [Full Text] [Related]  

  • 36. Late cardiotoxicity of anthracyclines in children with acute leukemia.
    Zalewska-Szewczyk B; Lipiec J; Bodalski J
    Klin Padiatr; 1999; 211(4):356-9. PubMed ID: 10472576
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anthracycline treatment and ventricular remodeling in left ventricular assist device patients.
    Segura AM; Radovancevic R; Demirozu ZT; Frazier OH; Buja LM
    Tex Heart Inst J; 2015 Apr; 42(2):124-30. PubMed ID: 25873821
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Familial dilated cardiomyopathy: another risk factor for anthracycline-induced cardiotoxicity?
    van den Berg MP; van Spaendonck-Zwarts KY; van Veldhuisen DJ; Gietema JA; Postma A; van Tintelen JP
    Eur J Heart Fail; 2010 Dec; 12(12):1297-9. PubMed ID: 20952769
    [No Abstract]   [Full Text] [Related]  

  • 39. Pathogenesis of cardiotoxicity induced by anthracyclines.
    Elliott P
    Semin Oncol; 2006 Jun; 33(3 Suppl 8):S2-7. PubMed ID: 16781283
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Anthracyclines and the heart].
    Mazzarello GP; Morra L
    Recenti Prog Med; 1998 Sep; 89(9):459-64. PubMed ID: 9796378
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.